OPTIMUM BIO
INNOVATIONS
LIMITED Improving Life
by optimizing Biology

Innovative research and development in biophysics

Optimum Bio Innovations Limited (OBIL) is an Auckland, New Zealand based Research and Development (R&D) company focusing on improving life through biophysics.

OBIL has developed a proprietary platform technology used as a basis upon which other applications, processes and technologies are developed.

The Company’s objective is to make an active contribution to future sustainable economic growth and jobs through the development and export of innovative, ethical and sustainable technologies.

The core technology, which is protected by trade secret, was derived as an accidental discovery while pursuing environmental science opportunities in 2012 – specifically in emission reduction.  It was discovered that the technology was having an unexpected effect of increased blood oxygenation.

In 2014 the first medical application of the current OBIL technology was born out of the Founder’s desperation to help his father manage debilitating symptoms from a range of life threatening illnesses.  Measurable results were observed in improved pain management, circulation, wound recovery and mental acuity.

Over the next three years (2014 – 2017) of research and development, over 100 people were directly impacted across a range of differing illnesses seeking symptom relief in one or more areas.

OBIL was established in 2017.

The Company’s focus is to develop application-specific Proof of Concepts (POCs) in New Zealand that will be spun out into separate, wholly-owned subsidiaries, each run by a team of specialists.

By 2024, over 40,000 hours have gone into R&D, to determine how the basis technology can be adapted and applied to further enhance life.

COMMERCIALIZED PROJECTS

Established 2022

OptiRTP

OptiRTP is a revolutionary innovation designed for in-home use, to relieve long-term chronic pain by amplifying recovery naturally.

OptiRTP’s proprietary signal is transmitted to the human body using sound and light, initiating a biochemical cascade of measurable physiological responses.

Under OptiRTP’s current medical registrations (US FDA and NZ Medsafe), the Company is targeting pain and accelerated wound recovery as complementary therapies to allopathic medicine – currently a $70 billion USD industry, estimated to grow to $116 billion USD by 2032.

Regular and consistent use of OptiRTP’s sound therapy seems to offer a more systemic benefit, whereas use of OptiRTP’s light therapy seems to offer a more targeted / localised benefit.  Many subscribers use both sound and light therapies on a daily basis.

Observations over the last eight years have shown benefits spanning across circulatory, respiratory and neurological conditions. These will be further explored in due course.

OptiRTP is offered as a monthly subscription digital therapeutic currently only available in New Zealand, with the objective to expand globally.

Visit OptiRTP Visit OptiRTP
ESTABLISHED 2022

OPTIMUM BIO
EQUINE THERAPY (OBET)

Optimum Bio Equine Therapy (OBET) provides accelerated recovery and conditioning for the elite equine athlete.

A US vet reviewed soft tissue pilot study has shown 50% reduction in recovery time for soft tissue injuries and OBET has been approved by the US Horseracing Integrity and Safety Board for use at all times up to 48 hours prior to a race.

OBET is a dynamic photo biomodulation therapy backed by over 40,000 hours of research and development in biophysics utilizing advanced analytics to calibrate biological responses.  This is what sets OBET apart from other ‘light therapy’ products which only deliver a static frequency – and is what allows OBET to adapt and deliver a customized therapy resulting in significantly reduced recovery times.

Visit OBET Solutions Visit OBET Solutions

CURRENT RESEARCH

Aquaponics / Hydroponics

Food Production

Abundant and nutritious food supply is an essential component to improving life.

OBIL’s basis technology provides benefits to living organism by affecting cellular respiration and increasing oxygen bioavailability.  These two concepts are being researched to refine an application to increase and improve food production using water as a carrier.

Preliminary scoping and very initial testing has been conducted.  OBIL plans to develop a more robust plan for delivery and testing of growth rates within the next 12 months.

More information will be posted as this project moves forward.